Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford will take part in a new pilot scheme to assess the use of Lateral Flow Tests (LFTs), a new COVID-19 test designed to identify asymptomatic individuals with the virus.

Coronavirus illustration

The Lateral Flow Test (LFT) is one of a number of new testing technologies for COVID-19 currently being trialled across the UK. It is hoped it will help identify those most at risk of spreading COVID-19 (those who are infectious, but not aware of this) and enable them to alter their behaviour accordingly, thereby breaking the chains of transmission and reducing the infection rate.

The pilot scheme, developed by Oxford in partnership with the Department of Health and Social Care, Public Health England and Durham University, will help us understand how best to use the technology and how it could be operationalised in the real world as part of broader COVID-19 testing strategies beyond the polymerise chain reaction (PCR) test.

The LFT produces results within a few minutes. Individuals swab their nose and throat to collect a sample, and then insert it into a tube of liquid for a short time. LFTs have already been validated and undergone clinical testing. If LFTs are able to detect enough people with the virus before they get symptoms, they could help prevent the spread of COVID-19.

Oxford is now rolling out the Feasibility and Acceptability of community COVID-19 rapid Testing Strategies (FACTS) study within the University community to assess how to organise using LFTs on a regular basis.

The full story is available on the University of Oxford website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.